Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone chips and cortical cancellous dental bone powders; and femoral, tibia, radius, and ulna shafts, femur distal, tibia proximal, and cervical spacer bones. In addition, the company offers medical devices for tissue regeneration, such as Rafugen DBM Gel Pro, Bio BMP2, BIOFIX SCREW, BIO MENISCUS GRAFT, SOLID W6, and viscoseal syringe; and joint reconstruction, comprising luminus flex total knee system fixed and mobile type and luminus flex patient specific instruments. Further, it is involved in biopharmaceutical development; construction machinery; food handling; and sales and brokerage of travel products. The company was formerly known as Korea Bone Bank Co., Ltd. and changed its name to Cellumed Co.,Ltd. in April 2013. Cellumed Co.,Ltd. was founded in 1985 and is headquartered in Seoul, South Korea.